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Abstract
Background: The feasibility of conducting a large-scale Polypill clinical trial in developing countries remains
unclear. More information is needed regarding the efficacy in reducing the risk factors of cardiovascular disease
(CVD), side effects, improvement in adherence and physician/patient “acceptability” of the Polypill.
Methods: We conducted an open-label, parallel-group, randomized clinical trial involving three sites in Sri Lanka
that enrolled a total of 216 patients without established CVD. The trial compared a Polypill (75 mg aspirin, 20 mg
simvastatin, 10 mg lisinopril and 12.5 mg hydrochlorothiazide) to Standard Practice. After randomization, patients
were followed monthly for three months. Pre-specified primary outcomes included reduction in systolic blood
pressure, total cholesterol and estimated 10-year CVD risk. We also evaluated the recruitment process and
acceptability of the Polypill by both physicians and patients.
Results: Patients were recruited in a six-month period as planned. Two hundred three patients (94.0%) completed
the treatment program and returned for their three-month follow-up visits. No safety concerns were reported.
These findings suggest a high rate of patient acceptability, a finding that is bolstered by the majority of patients
completing the trial (90%) indicating that they would take the Polypill “for life” if proven to be effective in reducing
CVD risk. Approximately 86% of the physicians surveyed agreed with and supported use of the Polypill for primary
prevention and 93% for secondary prevention of CVD. Both the Polypill and Standard Practice resulted in marked
reductions in systolic blood pressure, total cholesterol and 10-year risk of CVD. However, the differences between
the treatment groups were not statistically significant.
Conclusions: We successfully completed a Polypill feasibility trial in Sri Lanka. We were able to document high
acceptability of the Polypill to patients and physicians. We were unable to estimate the risk factor reductions on
the Polypill because the control group received similar treatment with individual drugs. The Polypill was however
simpler and achieved comparable risk factor reductions, highlighting its potential usefulness in the prevention of
CVD.
Trial registration number: ISRCTN: NCT00567307
Background
It has been well documented that aspirin [1], statins [2]
and antihypertensive interventions [3] reduce the risk of
cardiovascular disease (CVD). These benefits apply both
to patients with established CVD (secondary prevention)
and those at high risk of developing CVD (primary pre-
vention). Because these interventions exert their positive
effects through different mechanisms of action, one
might expect that their combined effects to be additive.
Wald and Law [4] introduced the concept of a so-called
Polypill, a combination of these treatments plus folic
acid. Even by using lower doses of the components, they
e s t i m a t e da no v e r a l l8 0 %r e d u c t i o ni nC V Dr i s kw i t h
the Polypill. A recently published primary prevention
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Study (TIPS), suggested that the overall benefit might be
closer to 60% [5]. The difference between the TIPS trial
estimates and the Wald and Law predictions can be
explained by the lower dose of simvastatin used in the
TIPS trial (20 mg rather than 40 mg) together with
non-adherence to treatment [6].
Prior to investing in large-scale, long-term, primary
prevention trials designed to determine CVD risk reduc-
tion with a fixed dose combination pill in low resource
settings several questions regarding feasibility need to be
addressed. Would physicians and patients accept the
long-term use of a fixed-dose combination pill? Would
the components of a Polypill cause side effects? Would
a Polypill improve adherence of patients? Would a Poly-
pill reduce CVD risk factors such as high cholesterol or
raised blood pressure and decrease CVD risk better than
standard treatment?
To address these questions and other relevant issues
such as study feasibility, we conducted a clinical trial
sponsored by the World Health Organization (WHO) in
Sri Lanka. The primary objectives of the trial included
estimation of CVD risk reduction and evaluation of side
effects of the Polypill and participant adherence to the
study intervention. Secondary aims focused on physician
and patient “acceptability” of the Polypill and feasibility
of the recruitment process.
Methods
Study design and population
We conducted an open-label, parallel-group, rando-
mized clinical trial comparing a Polypill to Standard
Practice (defined as usual care administered to patients
with similar conditions). From February 2, 2009 through
July 22, 2009, 591 patients were screened in three clini-
cal sites in Sri Lanka (The National Hospital of Sri
Lanka, Colombo; Teaching Hospital, Kegalle, and
Teaching Hospital, Kandy). Of the screened patients,
216 (36.5%) were enrolled and randomized, 105 to the
Polypill and 111 to the standard practice arm. Patients
were eligible for the study if they:
￿ Were ≥ 50 years old if female and ≥ 40 years if
male;
￿ Had an estimated 10-year total CVD risk score ≥
20%, based on country-specific WHO CVD risk pre-
diction charts [7]; and
￿ Had no contraindications to any of the compo-
nents included in the Polypill.
We excluded those with established CVD, advanced
kidney or liver diseases, other life-threatening diseases
and those who were unwilling to sign the informed
consent.
Intervention
A Polypill (Red Heart pill 2b, Reddy’s Laboratories,
India)c o n t a i n i n g7 5m ga s p i r i n ,2 0m gs i m v a s t a t i n ,
10 mg lisinopril and 12.5 mg hydrochlorothiazide was
compared to the level of Standard Practice as defined by
the study investigators. Decisions related to discontinuing
the study interventions or adding medications during
study participation were made at the discretion of the
specialist physicians who were in charge of patient care.
Study flow
Subsequent to granting written informed consent,
patients underwent screening and baseline evaluations
to confirm eligibility, followed by randomization to the
Polypill or to the Standard Practice study arm. Patients
receiving either intervention returned for a total of
three monthly clinic visits. Data collected included the
following:
￿ Specific questions about anticipated side effects
(monthly);
￿ General inquiry about other complaints (monthly);
￿ Adherence to study medication via pill count and
self report (monthly);
￿ Fasting levels of total cholesterol, blood sugar,
creatinine, potassium and liver enzymes (baseline
and 3 month visits)
￿ Estimated 10-year CVD total risk score using the
WHO CVD prediction chart [7]; the score is based
on systolic blood pressure and total cholesterol mea-
sures as well as on medical history data (monthly);
￿“ Acceptability” of the Polypill (evaluated in all
patients who completed the study [N = 203] as well
as in a sampling of screened but ineligible patients
(N = 207).
Physician survey
A five-question survey and the Wald and Law article
describing the concept of a Polypill [4] were mailed to
84 physicians from the participating clinical sites and
to the Council of General Practitioners in Sri Lanka.
All physicians subsequently received reminder phone
calls about completing the survey. A total of 58 (69%)
physicians (23 internists, 22 general practitioners, 11
cardiologists and 2 others) returned the survey. Physi-
cians were asked about their prior knowledge of the
Polypill concept, their agreement with Wald and Law
that there is no need to monitor CVD risk factors, and
their opinion about which factors would most affect
their decision to prescribe the Polypill. Finally, they
were asked about their acceptability in prescribing the
Polypill for purposes of primary and secondary preven-
tion of CVD.
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In estimating the sample size for our study, an assump-
tion was made that 200 patients would be needed to
achieve > 80% power at alpha = 0.05 in order to detect
a 6 mmHg difference in systolic blood pressure, a 12
mg/dl (0.31 mmol/L) difference in total cholesterol and
an approximate 3-5% absolute difference in the esti-
mated 10-year CVD risk between the two study groups.
The standard deviations around the mean baseline
values were assumed to be 14 mmHg and 20 mg/dl
for systolic blood pressure and total cholesterol,
respectively.
Frequency distributions for all variables were first
inspected to identify outliers possibly caused by mea-
surement errors. Descriptive statistics were presented as
means with standard deviations (SD) for all study parti-
cipants, stratified by intervention arm at baseline. Stu-
dent T and Chi square tests were employed to compare
changes in outcome variables between intervention
arms. All comparisons were made on an intention-to-
treat basis. A two-tailed p < 0.05 was considered signifi-
cant at alpha level of 0.05. SAS, version 9.1 (SAS
Institute, Inc., Cary, North Carolina) was used in all
analyses.
Ethical approval and registration
The World Health Organization Research Ethics Review
Committee, the Institutional Review Board of Wake For-
est University Health Sciences, and Sri Lanka Ministry
of Health approved this clinical trial. The trial is regis-
tered with ClinicalTrials.gov protocol registration sys-
tem, ID NCT00567307.
Results
Table 1 summarizes the characteristics of the study
population stratified by intervention assignment. Base-
line characteristics were generally well balanced across
the two study groups, with Polypill subjects exhibiting a
slightly higher level of total cholesterol compared to
patients in the Standard Practice group (P = 0.05).
Table 2 summarizes the post-randomization use of
non-study antihypertensive drugs and statins. Many
more patients in the Standard Practice group were tak-
ing these added medications compared to those in the
Polypill group (P < 0.01). The difference in use of anti-
hypertensive therapy was 89% vs 0% at one site and 40%
vs 5% at another, respectively. Use at the third site was
very high for both groups, 94% vs 90%. Trends for post-
randomization use of statins were similar, but less
pronounced.
Approximately 94% (N = 203) of the patients com-
pleted the trial (104 in the Standard Practice group and
99 in the Polypill group). Over 80% randomized to the
Polypill demonstrated >80% adherence to the pill, with
only 10%, 3%, and 6%, reporting <40%, 40-59% and 60-
79% adherence, respectively. In those who reported
adherence <80% (N = 19), 10 patients attributed their
low levels of adherence to side effects, 2 patients said
that they forgot to take the pill, and 7 patients did not
specify reasons. However, side effects and complaints
such as epigastric pain, cough and musculoskeletal pain
were comparable between the two study arms (Table 3).
There was no significant difference between the two
intervention groups with regard to reduction in esti-
mated 10-year CVD risk, systolic blood pressure, and
total cholesterol (Table 4). Other laboratory measures
(serum creatinine, potassium, and ALT) were also
comparable.
Patient acceptability
Approximately 90% of the patients completing the study
(93% in the Standard Practice group and 86% in the
Polypill group) indicated that they would “definitely” or
“probably” take the pill for life if it were shown to be
effective in reducing CVD risk. A similar response level
(89%) was obtained from those who were screened but
found to be ineligible for the study.
Physician acceptability
Physicians were fairly aware of the concept of the Poly-
pill (Table 5). Although they seemed skeptical about not
to monitor CVD risk factors (as suggested by Wald
Table 1 Baseline characteristics by treatment assignment
Overall
(N = 216)
Standard
Practice
(N = 111)
Polypill
(N = 105)
Gender (female) 157 (72.7%) 77 (69.4%) 80 (76.2%)
Age 59.1 ± 7.2 59.2 ± 7.4 59.0 ± 6.9
Smoking 11.2% 12.6% 9.7%
Estimated 10- year CVD
risk
10 - 19% 2 (0.9%) 0 (0.0%) 2 (1.9%)
20 - 29% 81 (38.2%) 48 (44.4%) 33 (31.7%)
30 - 39% 58 (27.4%) 27 (25.0%) 31 (29.8%)
40% or higher 71 (33.5%) 33 (30.6%) 38 (36.5%)
Systolic blood pressure
(mmHg)*
165.2 ± 18.2 164.7 ± 17.3 165.7 ± 19.2
Total cholesterol
(mmol/L)
5.9 ± 1.3 5.7 ± 1.3 6.1 ± 1.3
Fasting glucose
(mmol/L)
7.1 ± 2.7 7.1 ± 2.6 7.2 ± 2.8
Creatinine (mmol/L) 89.0 ± 21.8 90.4 ± 21.3 87.6 ± 22.3
Serum potassium
(mmol/L)
4.6 ± 0.6 4.6 ± 0.6 4.5 ± 0.5
ALT (U/L) 31.2 ± 16.7 32.0 ± 18.1 30.5 ± 15.1
Weight (kg) 57.2 ± 9.4 56.7 ± 9.2 57.8 ± 9.6
Height (cm) 152.8 ± 9.2 153.3 ± 9.2 152.3 ± 9.3
* Second measured blood pressure
Soliman et al. Trials 2011, 12:3
http://www.trialsjournal.com/content/12/1/3
Page 3 of 6and Law), they demonstrated high acceptability for pre-
scribing the Polypill as a therapeutic tool for both pri-
mary prevention (86%) and secondary prevention (93%).
Reduction in total 10-year CVD risk appeared to be the
most important factor that would factor into a decision
to prescribe the pill. These results did not vary by
specialty.
Discussion
Overall findings
The feasibility trial met several of our goals. Enrollment
of study patients went very well and was completed
according to the protocol-specified schedule. Most
patients in the Polypill group adhered to the study med-
ications. Only 6% of the enrollees did not complete the
treatment program and returned for the 3-month visit.
There were no reported safety concerns. These findings
are consistent with a high rate of patient acceptability.
The majority of patients completing the trial expressed
support for taking the Polypill for life if it were shown
to be effective in reducing CVD risk. Similarly, 86% of
physicians surveyed agreed with and supported the use
of the Polypill for primary prevention and 93% for sec-
ondary prevention of cardiovascular disease.
The double-blinded Indian Polycap Study (TIPS) eval-
uated the effects of several drug combinations on blood
pressure and lipids over 12 weeks. The Polycap reduced
systolic blood pressure by 7.4 mmHg and LDL choles-
terol by 0.70 mmol/L compared to no treatment. TIPS
excluded subjects who were taking any component
drugs included in the Polycap [5].
In contrast to TIPS, we did not detect any differences
between the Polypill and Standard Practice groups in
terms of reductions in systolic blood pressure, total cho-
lesterol or 10-year risk of cardiovascular disease. This
could relate to a number of problems that were revealed
during data analysis. It appears that the Standard Prac-
tice group received an unusually high level of care after
randomization, which, in turn, raised this study group’s
level of risk factor intervention to the level of the Poly-
pill group. The marked risk factor reductions observed
in both groups can possibly be explained by regression
to the mean. The large changes in blood pressures
between baseline and follow-up visits also raise ques-
tions about the standardization of these measurements.
Lessons learned
The centers involved in our study were tertiary care
hospitals. They do not reflect the level of medical care
provided at primary care centers and secondary level
hospitals in Sri Lanka. Thus, the findings from the
selected trial sites cannot be generalized to other levels
of care.
Furthermore, there is evidence that special attention
was given to Standard Practice patients. At two sites, a
much higher proportion of them were prescribed anti-
hypertensive drugs and statins compared to those in
the Polypill group. At the third site, a large proportion
of enrolled patients received antihypertensive therapy
and statins. Regardless of the details of treatment pre-
scribed, which would be of limited value here, this use
of non-study drugs defeated the objective of the trial
by making it difficult to observe the expected treat-
ment effect of the Polypill. Clearly the open-label
design of our study undermined our ability to properly
test the Polypill.
Table 2 Post-randomization use of non-study antihypertensive drugs and statins
Site Medications Standard Practice Polypill P-value
Kegalle Teaching Hospital Antihypertensive use 8/20 (40.0%) 1/21 (4.8%) < 0.01
Statin use 5/20 (25.0%) 0/21 (0.0%) 0.01
Kandy Teaching Hospital Antihypertensive use 33/37 (89.2%) 0/34 (0.0%) < 0.01
Statin use 29/37 (78.4%) 2/30 (6.7%) < 0.01
The National Hospital of Sri Lanka Antihypertensive use 51/54 (94.4%) 45/50 (90.0%) 0.40
Statin use 41/54 (75.9%) 35/50 (70.0%) 0.50
All sites (Total Sample) Antihypertensive use 92/111 (82.9%) 46/105 (43.8%) < 0.01
Statin use 75/111 (67.6%) 37/101 (36.6%) < 0.01
Table 3 Cumulative frequency of major side effects during the 3-month treatment period by study group
Standard Practice
(N = 104)
Polypill
(N = 99)
Odds ratio (95% CI) p-value
Epigastric pain 20/104 (19.2%) 15/97 (15.5%) 1.30 (0.62, 2.72) 0.482
Musculoskeletal pain 29/104 (27.9%) 26/97 (26.8%) 1.06 (0.57, 1.96) 0.864
Cough 18/104 (17.3%) 25/97 (25.8%) 0.60 (0.30, 1.19) 0.144
Other symptoms 12/104 (11.5%) 15/97 (15.5%) 0.71 (0.32, 1.61) 0.415
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Practice group during the 3-month treatment period is
not known. Such adjustments could have further dimin-
ished the study group differences for systolic blood pres-
sure and total cholesterol.
Based on the challenges we encountered in our trial,
we think that there are four design options to consider
for future Polypill studies. First, would be to conduct
the trial on people above 50 years of age and not focus
on risk factor measurement. Second, would be to follow
the suggestion by Wald and Law [4] and not monitor
the risk factors. Third, would be to recruit a low risk
population in which treatment of risk factors would be
much less prevalent. Fourth, would be to strongly
Table 4 Change in estimated 10-year CVD risk and key measures at study closeout
Standard Practice
(N = 104)
Polypill
(N = 99)
Baseline Exit Diff Baseline Exit Diff Diff of Differences
(95% CI)
P-value
Estimated 10-year CVD risk (%) 41.6 ± 19.8 11.1 ± 10.0 -30.6 ± 22.8 44.1 ± 20.3 11.5 ± 13.0 -32.7 ± 26.0 2.1 (-4.9, 9.1) 0.56
Systolic blood pressure (mmHg)* 165.0 ± 17.6 138.1 ± 19.3 -26.9 ± 25.7 165.6 ± 19.2 136.8 ± 20.8 -28.8 ± 24.9 1.9 (-5.1, 8.9) 0.60
Total cholesterol (mmol/L) 5.7 ± 1.3 4.7 ± 1.1 -1.0 ± 1.6 6.1 ± 1.3 4.8 ± 1.0 -1.4 ± 1.2 0.4 (0.0, 0.8) 0.07
Creatinine (mmol/L) 90.5 ± 21.2 92.8 ± 24.6 1.3 ± 19.3 87.8 ± 22.6 92.9 ± 25.9 4.8 ± 31.7 -3.5 (-10.8, 3.8) 0.36
Serum potassium (mmol/L) 4.6 ± 0.6 4.5 ± 0.4 -0.0 ± 0.5 4.5 ± 0.5 4.6 ± 0.5 0.1 ± 0.6 -0.1 (-0.3, 0.1) 0.10
Alanine aminotransferase (U/L) 31.9 ± 18.2 36.3 ± 31.6 4.1 ± 25.7 29.8 ± 15.0 33.0 ± 26.0 3.0 ± 17.8 1.1(-5.1, 7.3) 0.72
* Second measured blood pressure.
Table 5 Physician survey results
Question Summary response
Q1: Knowledge of the Polypill concept
It has been hypothesized through a meta-analysis that a daily intake of a so-called Polypill (fixed combination of
low dose ACE-I, statin, diuretic and aspirin) for life long may reduce the risk of CVD by more than 80%. These
results, according to the hypothesis, are applicable to primary and secondary prevention. In a scale from 1 to 10
where 1 is the least and 10 is the maximum, how do you rate your knowledge about the Polypill?
Mean (SD); Median (Minimum,
Maximum)
5.6 (2.2); 6.0 (1.0, 10.0)
Q2: Agreement with Wald & Law on lack of need to routinely monitor CVD risk factors
The polypill strategy, as suggested by the authors, does not require routine monitoring or measuring the
cardiovascular risk factors (such as blood pressure or cholesterol) in patients receiving the Polypill. This has been
rationalized by the notion that CVD risk reduction by the Polypill is independent from the baseline value. In a scale
from 1 to 10 where 1 is the least and 10 is the maximum, how do you rate your agreement on not to monitor the
CVD risk factors in patients receiving the Polypill?
Mean (SD); Median (Minimum,
Maximum)
2.9 (2.4); 2.0(1.0, 10.0)
Q3: Most important factor for prescribing a Polypill
What would be the most important factor that determine your decision to prescribe the Polypill:
N (%)
Few side effects 11(19.3)
Degree of CVD risk reduction 28 (49.1)
Low cost 5 (8.7)
Others 14 (24.6)
Q4: Acceptability to prescribe the Polypill for PRIMARY CVD prevention
If it is documented in a large clinical trial that a daily intake of the Polypill reduces the risk of major CVD in people
without established CVD (primary prevention), will you prescribe it to your patients?
N (%)
Yes, definitely 39(67.2)
Yes, probably 11(19.0)
No 8 (13.8)
Q5: Acceptability to prescribe the Polypill for SECONDARY CVD prevention
If it is documented in a large clinical trial that a daily intake of the Polypill reduces the risk of recurrent
cardiovascular event in people with established CVD (secondary prevention) will you prescribe it to your patients?
N, (%)
Yes, definitely 50 (86.2)
Yes, probably 4 (6.9)
No 4(6.9)
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ment after randomization
Conclusions
We successfully completed a Polypill feasibility trial in
Sri Lanka. We were able to document high acceptability
of the Polypill to patients and physicians. We were
unable to estimate the risk factor reductions on the
Polypill because the control group received similar treat-
ment with individual drugs. The Polypill was however
simpler and achieved comparable risk factor reductions,
highlighting its potential usefulness in the prevention of
CVD. Further studies assessing the Polypill in develop-
ing countries should take into consideration the study
design lessons and challenges that we encountered.
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